In July 2026, a federal judge in Michigan sentenced Brandon Piper after prosecutors reported he sold imported peptides, semaglutide, and tirzepatide through websites that marketed the products for research purposes only.
Federal Sentencing Follows Online Sales of Imported Peptides and GLP-1 Drugs
On July 23, 2026, the U.S. Attorney’s Office for the Western District of Michigan reported that Brandon Piper, 35, of Gobles, Michigan, was sentenced to 21 months in federal prison for conspiring to introduce misbranded drugs into the market. The case involved imported peptides, semaglutide, and tirzepatide from China, sold through websites that described the products as intended for research use only. For Med Spa and wellness operators that offer peptides, GLP-1 medications, or similar products, the case involves drug sourcing, prescription requirements, and labeling.
Key Case Details on Misbranded Drug Conspiracy and Fraud
In a July 23, 2026 press release, the U.S. Attorney’s Office for the Western District of Michigan reported that Piper was sentenced for participating in a scheme to import unapproved and misbranded prescription drugs from China for distribution to customers in the United States. Citing sentencing filings, the U.S. Attorney’s Office stated that customers initially purchased the products through a Canadian website and later through Piper’s website.
Both websites described the drugs as “for research purposes only,” although the sentencing filings stated that Piper and his co-conspirators knew customers intended to use them personally. The government also reported that many products were represented as a “Product of the USA” despite being purchased from China. The press release identified semaglutide and tirzepatide among the drugs sold through the websites, and stated that both drugs require a prescription from a licensed practitioner before they can be dispensed. The press release stated that customers were sold the products without prescriptions and received shipments without adequate directions for use.
The office also reported that Piper’s semaglutide and tirzepatide products omitted boxed warnings addressing the risk of thyroid C-cell tumors that appear on FDA-approved versions of the drugs. U.S. District Judge Robert J. Jonker sentenced Piper to 21 months in prison for conspiracy to introduce misbranded drugs into the market with intent to defraud and mislead the FDA and consumers. Piper’s co-defendant, Mayze Nichols, is scheduled to be sentenced on related charges on September 15, 2026.
U.S. Attorney’s Office Press Release
According to the July 23, 2026 press release from the U.S. Attorney’s Office for the Western District of Michigan, the sentencing followed a federal case involving imported unapproved and misbranded prescription drugs sold through online websites.
Compliance Considerations for Peptide and GLP-1 Sourcing in Med Spa and Wellness Clinics
This federal case centers on the sale of imported prescription drugs, including peptides, outside established prescribing, sourcing, and labeling requirements. In the Piper case, the U.S. Attorney’s Office reported that semaglutide and tirzepatide were sold without prescriptions, shipped without adequate directions for use, and marketed through websites that described the products as intended for research purposes only. Federal law prohibits introducing or delivering misbranded drugs into interstate commerce under 21 U.S.C. § 331(a).
FDA regulations at 21 C.F.R. § 201.5 define adequate directions for use as directions under which a layperson can use a drug safely and for its intended purposes. The FDA also identifies a drug as misbranded when its labeling does not bear adequate directions for use.
The case follows other recent enforcement matters involving similar products. In July 2026, a federal court sentenced the owner of Paradigm Peptides in a case involving unapproved drugs sold through an online peptide business. A separate North Carolina case involves charges alleging unlicensed prescribing and distribution of tirzepatide.
For Med Spa and wellness clinics that offer peptides or GLP-1 medications, the case involves product origin, supplier authorization, prescription requirements, and labeling requirements before products are provided to patients. FDA guidance and the U.S. Code establish requirements related to drug labeling, distribution, and misbranding that may apply to prescription drugs offered through Med Spa and wellness settings.
FDA guidance and the U.S. Code establish requirements related to drug labeling, distribution, and misbranding.
Practical Implications for Med Spa and Wellness Operators
- Verify the source, manufacturer, supplier, and distribution pathway for peptides, GLP-1 medications, and other prescription drugs obtained for patient use.
- Confirm that an appropriately authorized provider is involved when a prescription is required before a medication is dispensed or administered.
- Review product labeling, warnings, directions for use, and country-of-origin information before stocking, dispensing, or administering medications.
- Evaluate supplier and distributor claims about where products are made, how they are tested, and whether they are labeled “for research purposes only.”
- Ensure lawful pathways and accurate website marketing for peptides, GLP-1 medications, and their intended use.
What to Watch Next
As of this reporting, Piper’s co-defendant, Mayze Nichols, is scheduled for sentencing on September 15, 2026. Further court filings and case developments may provide additional details about the federal case and related peptide and GLP-1 products. FDA guidance and applicable federal, state, and local requirements remain important reference points for Med Spa, aesthetics, and wellness clinics offering these products.
About Spakinect
Spakinect provides compliance infrastructure and telehealth-supported supervision solutions for medical aesthetic practices. For additional information, see our website.
Image Attribution: “Courtroom Gavel” by onaeg news agency, via Wikimedia Commons, licensed under CC BY-SA 4.0.
